Latest / Community Health Media
Dr. Mark Pegram & Dr. Ana Garrido-Castro – Breakthrough Data in Metastatic TNBC
At ESMO Berlin, Dr. Mark Pegram and Dr. Ana Garrido-Castro break down breakthrough data shaping the new standard for first-line metastatic triple-negative breast cancer (TNBC).
Together, they unpack results from ASCENT-03 and TROPION-Breast02, where Trop-2 antibody-drug conjugates demonstrated significant improvements in response rates, PFS, and — in one study — overall survival.
Drs. Pegram and Garrido-Castro explore:
• Why Trop-2 ADCs may replace chemotherapy in PD-L1–negative TNBC
• Key differences in trial design, patient selection, and endpoints
• Real-world decision-making based on…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.